|
www.aurobindo.com |
|
|
Hyderabad, 16th March, 2006 |
|
|
|
AUROBINDO'S RECEIVES US
FDA APPROVAL FOR LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLET |
|
|
|
This is Aurobindo’s First
final approval for any combination product for
the US market. |
|
Aurobindo Pharma is
pleased to announce that the US FDA has approved
Aurobindo’s Lisinopril and Hydrochlorothiazide
tablets, 10/12.5 mg, 20/12.5 mg, and 20/25 mg. |
|
The market opportunity for
the above product is around USD 100 Million.
With this approval Aurobindo’s product basket
for the USA market has gone upto Eleven. |
|
This combination belongs to
the class of medicines called high blood
pressure medicines (antihypertensives). It is
used to treat high blood pressure
(hypertension). |
|
Lisinopril and
Hydrochlorothiazide tablets, 10/12.5 mg, 20/12.5
mg, and 20/25 mg is the generic version of
Prinzide Tablets, 10/12.5 mg, 20/12.5 mg, and
20/25 mg of Merck research Laboratories. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company has
received approvals for several facilities from
leading regulatory agencies like US FDA, UK MHRA,
WHO, Health Canada, MCC South Africa. The
company’s robust product portfolio is spread
over 6 major therapeutic/product areas
encompassing (Antibiotics, Anti-Retrovirals,
CVS, CNS, Gastroenterologicals, and Anti-Allergics)
around 65 APIs in the non-antibiotics and 55
APIs in the antibiotic segment. The Company is
marketing these products globally, in over 100
countries. |
|
|
|
|
|
PRESS
ROOM
